bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
![Bausch Health Companies logo](/files/LOGO/885590-BHC.png)
Company profile
Ticker
BHC
Exchange
Website
CEO
Thomas J. Appio
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • AcuFocus Australia • Bausch Health Australia Pty Limited • Bausch & Lomb (Australia) Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...
BHC stock data
Latest filings (excl ownership)
8-K
Bausch Health Welcomes Two New Members to the Executive Leadership Team
19 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
15 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Bausch Health Announces First Quarter 2024 Results
2 May 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Bausch Health Announces Fourth-quarter and Full-year 2023 Results
22 Feb 24
8-K
Bausch Health Announces Board Refreshment
1 Feb 24
Transcripts
BHC
Earnings call transcript
2024 Q1
2 May 24
BHC
Earnings call transcript
2023 Q4
22 Feb 24
BHC
Earnings call transcript
2023 Q3
2 Nov 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q3
3 Nov 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm |
Cash burn (monthly) | 69.00 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 266.76 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 488.24 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 7.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
81.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 237 |
Opened positions | 92 |
Closed positions | 26 |
Increased positions | 33 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 2.80 tn |
Total shares | 292.72 mm |
Total puts | 20.38 mm |
Total calls | 20.24 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Icahn Carl C Et Al | 34.72 mm | $368.39 bn |
Goldentree Asset Management | 27.64 mm | $293.31 bn |
Paulson & Co. | 26.44 mm | $280.52 bn |
BEN Franklin Resources | 15.85 mm | $168.18 bn |
NA.R National Bank of Canada | 15.66 mm | $107.75 bn |
NMR Nomura | 15.37 mm | $163.08 bn |
VA Partners I | 14.43 mm | $135.65 mm |
Healthcare Of Ontario Pension Plan Trust Fund | 13.00 mm | $137.93 bn |
Hudson Bay Capital Management | 11.75 mm | $124.67 bn |
RY Royal Bank Of Canada | 11.72 mm | $124.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jul 24 | John S Barresi | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 49,254 | 0.00 | 154,388 |
15 Jul 24 | Aimee J. Lenar | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 144,352 | 0.00 | 144,352 |
28 Jun 24 | Brett Icahn | Common Shares, No Par Value | Grant | Acquire A | No | No | 6.97 | 4,752 | 33.12 k | 148,612 |
28 Jun 24 | Paulson John | Common Shares, No Par Value | Grant | Acquire A | No | No | 6.97 | 8,967 | 62.50 k | 252,636 |
News
Truist Securities Maintains Hold on Bausch Health Companies, Lowers Price Target to $7
25 Jul 24
Why Bausch health Shares Are Falling Today
24 Jul 24
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
24 Jul 24
Bausch Health Responds To Market Rumors; Says "The Article Contains Unsubstantiated Rumors, Including That The Company Is Considering A Bankruptcy Or Insolvency Proceeding Of Any Kind - It Is Not."
24 Jul 24
Bausch Health Companies Says Jean-Jacques Charhon Will Join Company As CFO On August 19, 2024 - Filing
19 Jul 24
Press releases
Bausch Health Responds to Market Rumors
24 Jul 24
Bausch Health Welcomes Two New Members to the Executive Leadership Team
19 Jul 24
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
11 Jul 24
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
14 Jun 24
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
23 May 24